Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.

Griffiths EA, Srivastava P, Matsuzaki J, Brumberger Z, Wang ES, Kocent J, Miller A, Roloff GW, Wong HY, Paluch BE, Lutgen-Dunckley LG, Martens BL, Odunsi K, Karpf AR, Hourigan CS, Nemeth MJ.

Clin Cancer Res. 2018 Mar 1;24(5):1019-1029. doi: 10.1158/1078-0432.CCR-17-1792. Epub 2017 Sep 25.

PMID:
28947565
2.

White blood cell DNA methylation and risk of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).

Sturgeon SR, Pilsner JR, Arcaro KF, Ikuma K, Wu H, Kim SM, Chopra-Tandon N, Karpf AR, Ziegler RG, Schairer C, Balasubramanian R, Reckhow DA.

Breast Cancer Res. 2017 Aug 18;19(1):94. doi: 10.1186/s13058-017-0886-6.

3.

G-1 Inhibits Breast Cancer Cell Growth via Targeting Colchicine-Binding Site of Tubulin to Interfere with Microtubule Assembly.

Lv X, He C, Huang C, Hua G, Wang Z, Remmenga SW, Rodabough KJ, Karpf AR, Dong J, Davis JS, Wang C.

Mol Cancer Ther. 2017 Jun;16(6):1080-1091. doi: 10.1158/1535-7163.MCT-16-0626. Epub 2017 Mar 3.

PMID:
28258163
4.

The four and a half LIM domains 2 (FHL2) regulates ovarian granulosa cell tumor progression via controlling AKT1 transcription.

Hua G, He C, Lv X, Fan L, Wang C, Remmenga SW, Rodabaugh KJ, Yang L, Lele SM, Yang P, Karpf AR, Davis JS, Wang C.

Cell Death Dis. 2016 Jul 14;7:e2297. doi: 10.1038/cddis.2016.207.

5.

PRAME expression and promoter hypomethylation in epithelial ovarian cancer.

Zhang W, Barger CJ, Eng KH, Klinkebiel D, Link PA, Omilian A, Bshara W, Odunsi K, Karpf AR.

Oncotarget. 2016 Jul 19;7(29):45352-45369. doi: 10.18632/oncotarget.9977.

6.

DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer.

Klinkebiel D, Zhang W, Akers SN, Odunsi K, Karpf AR.

Mol Cancer Res. 2016 Sep;14(9):787-94. doi: 10.1158/1541-7786.MCR-16-0097. Epub 2016 Jun 3.

7.

Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease.

Haley J, Tomar S, Pulliam N, Xiong S, Perkins SM, Karpf AR, Mitra S, Nephew KP, Mitra AK.

Oncotarget. 2016 May 31;7(22):32810-20. doi: 10.18632/oncotarget.9053.

8.

Promoter Hypomethylation and Expression Is Conserved in Mouse Chronic Lymphocytic Leukemia Induced by Decreased or Inactivated Dnmt3a.

Haney SL, Upchurch GM, Opavska J, Klinkebiel D, Hlady RA, Suresh A, Pirruccello SJ, Shukla V, Lu R, Costinean S, Rizzino A, Karpf AR, Joshi S, Swanson P, Opavsky R.

Cell Rep. 2016 May 10;15(6):1190-201. doi: 10.1016/j.celrep.2016.04.004. Epub 2016 Apr 28.

9.

Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy.

Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Blagitko-Dorfs N, Ford LA, Naqash R, L├╝bbert M, Karpf AR, Nemeth MJ, Griffiths EA.

Oncotarget. 2016 Mar 15;7(11):12840-56. doi: 10.18632/oncotarget.7326.

10.

Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.

Barger CJ, Zhang W, Hillman J, Stablewski AB, Higgins MJ, Vanderhyden BC, Odunsi K, Karpf AR.

Oncotarget. 2015 Sep 29;6(29):27613-27. doi: 10.18632/oncotarget.4546.

11.

DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.

Zhang W, Barger CJ, Link PA, Mhawech-Fauceglia P, Miller A, Akers SN, Odunsi K, Karpf AR.

Epigenetics. 2015;10(8):736-48. doi: 10.1080/15592294.2015.1062206.

12.

Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.

Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Taverna P, Karpf AR, Griffiths EA.

Epigenetics. 2015;10(3):237-46. doi: 10.1080/15592294.2015.1017198.

13.

Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.

Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Karbach J, Nemeth MJ, Taverna P, Karpf AR, Griffiths EA.

Leuk Res. 2014 Nov;38(11):1332-41. doi: 10.1016/j.leukres.2014.09.001. Epub 2014 Sep 10.

14.

Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.

Odunsi K, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T, Miller A, Zhang W, Akers SN, Griffiths EA, Miliotto A, Beck A, Batt CA, Ritter G, Lele S, Gnjatic S, Karpf AR.

Cancer Immunol Res. 2014 Jan;2(1):37-49. doi: 10.1158/2326-6066.CIR-13-0126.

15.

LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients.

Akers SN, Moysich K, Zhang W, Collamat Lai G, Miller A, Lele S, Odunsi K, Karpf AR.

Gynecol Oncol. 2014 Feb;132(2):462-7. doi: 10.1016/j.ygyno.2013.12.024. Epub 2013 Dec 25.

16.

Tumor suppressor functions of Dnmt3a and Dnmt3b in the prevention of malignant mouse lymphopoiesis.

Peters SL, Hlady RA, Opavska J, Klinkebiel D, Pirruccello SJ, Talmon GA, Sharp JG, Wu L, Jaenisch R, Simpson MA, Karpf AR, Opavsky R.

Leukemia. 2014 May;28(5):1138-42. doi: 10.1038/leu.2013.364. Epub 2013 Dec 2. No abstract available.

PMID:
24292811
17.

Essential role for Dnmt1 in the prevention and maintenance of MYC-induced T-cell lymphomas.

Peters SL, Hlady RA, Opavska J, Klinkebiel D, Novakova S, Smith LM, Lewis RE, Karpf AR, Simpson MA, Wu L, Opavsky R.

Mol Cell Biol. 2013 Nov;33(21):4321-33. doi: 10.1128/MCB.00776-13. Epub 2013 Sep 3.

18.

SGI-110: DNA Methyltransferase Inhibitor Oncolytic.

Griffiths EA, Choy G, Redkar S, Taverna P, Azab M, Karpf AR.

Drugs Future. 2013 Aug;38(8):535-543.

19.

DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11.

James SR, Cedeno CD, Sharma A, Zhang W, Mohler JL, Odunsi K, Wilson EM, Karpf AR.

Epigenetics. 2013 Aug;8(8):849-63. doi: 10.4161/epi.25500. Epub 2013 Jul 9.

20.

Genome-wide hypomethylation and cancer risk--letter.

Karpf AR.

Cancer Prev Res (Phila). 2013 Jul;6(7):753. doi: 10.1158/1940-6207.CAPR-13-0162. Epub 2013 Jun 10. No abstract available.

21.

BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.

Link PA, Zhang W, Odunsi K, Karpf AR.

Cancer Immun. 2013;13:6. Epub 2013 Jan 22.

22.

Dnmt3b is a haploinsufficient tumor suppressor gene in Myc-induced lymphomagenesis.

Vasanthakumar A, Lepore JB, Zegarek MH, Kocherginsky M, Singh M, Davis EM, Link PA, Anastasi J, Le Beau MM, Karpf AR, Godley LA.

Blood. 2013 Mar 14;121(11):2059-63. doi: 10.1182/blood-2012-04-421065. Epub 2013 Jan 11.

23.

Epigenetic alterations in oncogenesis. Preface.

Karpf AR.

Adv Exp Med Biol. 2013;754:v-vii. No abstract available.

PMID:
23189391
24.

Synergism between clofarabine and decitabine through p53R2: a pharmacodynamic drug-drug interaction modeling.

Thudium KE, Ghoshal S, Fetterly GJ, Haese JP, Karpf AR, Wetzler M.

Leuk Res. 2012 Nov;36(11):1410-6. doi: 10.1016/j.leukres.2012.07.015. Epub 2012 Aug 9.

25.

NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.

Ademuyiwa FO, Bshara W, Attwood K, Morrison C, Edge SB, Karpf AR, James SA, Ambrosone CB, O'Connor TL, Levine EG, Miliotto A, Ritter E, Ritter G, Gnjatic S, Odunsi K.

PLoS One. 2012;7(6):e38783. doi: 10.1371/journal.pone.0038783. Epub 2012 Jun 28. Erratum in: PLoS One.2012;7(8). doi:10.1371/annotation/5cdf6105-2a52-497a-86b3-db8f4a4e439c. Karpf, Adam R [added]; James, Smith A [added].

26.

Insufficient DNA methylation affects healthy aging and promotes age-related health problems.

Liu L, van Groen T, Kadish I, Li Y, Wang D, James SR, Karpf AR, Tollefsbol TO.

Clin Epigenetics. 2011 Aug;2(2):349-60. doi: 10.1007/s13148-011-0042-6. Epub 2011 Jun 12.

27.

Differential vitamin D 24-hydroxylase/CYP24A1 gene promoter methylation in endothelium from benign and malignant human prostate.

Deeb KK, Luo W, Karpf AR, Omilian AR, Bshara W, Tian L, Tangrea MA, Morrison CD, Johnson CS, Trump DL.

Epigenetics. 2011 Aug;6(8):994-1000. doi: 10.4161/epi.6.8.16536. Epub 2011 Aug 1.

28.

Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss.

Klein CJ, Botuyan MV, Wu Y, Ward CJ, Nicholson GA, Hammans S, Hojo K, Yamanishi H, Karpf AR, Wallace DC, Simon M, Lander C, Boardman LA, Cunningham JM, Smith GE, Litchy WJ, Boes B, Atkinson EJ, Middha S, B Dyck PJ, Parisi JE, Mer G, Smith DI, Dyck PJ.

Nat Genet. 2011 Jun;43(6):595-600. doi: 10.1038/ng.830. Epub 2011 May 1.

29.

Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage.

Woloszynska-Read A, Zhang W, Yu J, Link PA, Mhawech-Fauceglia P, Collamat G, Akers SN, Ostler KR, Godley LA, Odunsi K, Karpf AR.

Clin Cancer Res. 2011 Apr 15;17(8):2170-80. doi: 10.1158/1078-0432.CCR-10-2315. Epub 2011 Feb 4.

30.

BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines.

Woloszynska-Read A, James SR, Song C, Jin B, Odunsi K, Karpf AR.

Cancer Immun. 2010 Jul 23;10:6.

31.

Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer.

Luo W, Karpf AR, Deeb KK, Muindi JR, Morrison CD, Johnson CS, Trump DL.

Cancer Res. 2010 Jul 15;70(14):5953-62. doi: 10.1158/0008-5472.CAN-10-0617. Epub 2010 Jun 29.

32.

Opposing roles of Dnmt1 in early- and late-stage murine prostate cancer.

Kinney SR, Moser MT, Pascual M, Greally JM, Foster BA, Karpf AR.

Mol Cell Biol. 2010 Sep;30(17):4159-74. doi: 10.1128/MCB.00235-10. Epub 2010 Jun 28.

33.

Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy.

Akers SN, Odunsi K, Karpf AR.

Future Oncol. 2010 May;6(5):717-32. doi: 10.2217/fon.10.36. Review.

34.

Mechanisms of epigenetic silencing of the Rassf1a gene during estrogen-induced breast carcinogenesis in ACI rats.

Starlard-Davenport A, Tryndyak VP, James SR, Karpf AR, Latendresse JR, Beland FA, Pogribny IP.

Carcinogenesis. 2010 Mar;31(3):376-81. doi: 10.1093/carcin/bgp304. Epub 2009 Dec 14.

35.

Dnmt3 and G9a cooperate for tissue-specific development in zebrafish.

Rai K, Jafri IF, Chidester S, James SR, Karpf AR, Cairns BR, Jones DA.

J Biol Chem. 2010 Feb 5;285(6):4110-21. doi: 10.1074/jbc.M109.073676. Epub 2009 Nov 29.

36.

Lack of evidence for green tea polyphenols as DNA methylation inhibitors in murine prostate.

Morey Kinney SR, Zhang W, Pascual M, Greally JM, Gillard BM, Karasik E, Foster BA, Karpf AR.

Cancer Prev Res (Phila). 2009 Dec;2(12):1065-75. doi: 10.1158/1940-6207.CAPR-09-0010. Epub 2009 Nov 24.

37.

Association between global DNA hypomethylation in leukocytes and risk of breast cancer.

Choi JY, James SR, Link PA, McCann SE, Hong CC, Davis W, Nesline MK, Ambrosone CB, Karpf AR.

Carcinogenesis. 2009 Nov;30(11):1889-97. doi: 10.1093/carcin/bgp143. Epub 2009 Jul 7.

38.

Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells.

Link PA, Gangisetty O, James SR, Woloszynska-Read A, Tachibana M, Shinkai Y, Karpf AR.

Mol Cancer Res. 2009 Jun;7(6):851-62. doi: 10.1158/1541-7786.MCR-08-0497. Epub 2009 Jun 16.

39.

Expression level and DNA methylation status of glutathione-S-transferase genes in normal murine prostate and TRAMP tumors.

Mavis CK, Morey Kinney SR, Foster BA, Karpf AR.

Prostate. 2009 Sep 1;69(12):1312-24. doi: 10.1002/pros.20976.

40.

Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP.

Karpf AR, Bai S, James SR, Mohler JL, Wilson EM.

Mol Cancer Res. 2009 Apr;7(4):523-35. doi: 10.1158/1541-7786.MCR-08-0400.

41.

DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, and gadd45.

Rai K, Huggins IJ, James SR, Karpf AR, Jones DA, Cairns BR.

Cell. 2008 Dec 26;135(7):1201-12. doi: 10.1016/j.cell.2008.11.042.

42.
43.

Epigenetic alterations in the brains of Fisher 344 rats induced by long-term administration of folate/methyl-deficient diet.

Pogribny IP, Karpf AR, James SR, Melnyk S, Han T, Tryndyak VP.

Brain Res. 2008 Oct 27;1237:25-34. doi: 10.1016/j.brainres.2008.07.077. Epub 2008 Jul 30.

PMID:
18694733
44.

Stage-specific alterations of DNA methyltransferase expression, DNA hypermethylation, and DNA hypomethylation during prostate cancer progression in the transgenic adenocarcinoma of mouse prostate model.

Morey Kinney SR, Smiraglia DJ, James SR, Moser MT, Foster BA, Karpf AR.

Mol Cancer Res. 2008 Aug;6(8):1365-74. doi: 10.1158/1541-7786.MCR-08-0040. Epub 2008 Jul 30.

45.

Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer.

Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, Odunsi K, Karpf AR.

Clin Cancer Res. 2008 Jun 1;14(11):3283-90. doi: 10.1158/1078-0432.CCR-07-5279.

46.

Phenotype-specific CpG island methylation events in a murine model of prostate cancer.

Camoriano M, Kinney SR, Moser MT, Foster BA, Mohler JL, Trump DL, Karpf AR, Smiraglia DJ.

Cancer Res. 2008 Jun 1;68(11):4173-82. doi: 10.1158/0008-5472.CAN-07-6715.

47.

Genetic and epigenetic changes in rat preneoplastic liver tissue induced by 2-acetylaminofluorene.

Bagnyukova TV, Tryndyak VP, Montgomery B, Churchwell MI, Karpf AR, James SR, Muskhelishvili L, Beland FA, Pogribny IP.

Carcinogenesis. 2008 Mar;29(3):638-46. doi: 10.1093/carcin/bgm303. Epub 2008 Jan 19.

PMID:
18204080
48.

DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer.

Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR.

Cancer Immun. 2007 Dec 21;7:21.

50.

Supplemental Content

Loading ...
Support Center